Enliven Therapeutics, Inc.
ELVNNASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $2.60B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $14.79$62.32
- Volume (live)
- -
- Avg. volume (3M)
- 1.43M
Enliven Therapeutics (ELVN) Stock Price & Financial Analysis
Enliven Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $38.49 - $40.29 |
|---|---|
| 52-Week High | $62.32 |
| 52-Week Low | $14.79 |
| Open | $39.48 |
| Volume (last close) | 2.05M |
| Average Volume (3M) | 1.43M |
| 50-Day MA | $52.91 |
|---|---|
| 200-Day MA | $41.40 |
| 1-Year Change | +80.83% |
| Market Cap | 2.60B |
|---|---|
| Shares Outstanding | 66.17M |
| Price to Book (P/B) | 2.91 |
| EV/EBITDA | -21.38 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Enliven Therapeutics at a Glance
As of the Oct 15, 2026 close, Enliven Therapeutics (ELVN) has a market capitalization of $2.60B.
As of its latest reported balance sheet, it holds $135.50M in cash and securities against $1.51M of debt, a net cash position of $134.00M.
Enliven Therapeutics does not currently pay a dividend.
The share price is up 80.8% over the past year. At $39.33 (the Oct 15, 2026 close) it sits within its 52-week range of $14.79 to $62.32, below its 200-day moving average of $41.40.
Based on 13 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $74.45, 89.3% above the Oct 15, 2026 close.
Frequently Asked Questions About Enliven Therapeutics
What is the current stock price for ELVN?
As of the Oct 15, 2026 close, ELVN stock trades at $39.33. The 52-week range is $14.79–$62.32, with a day range of $38.49–$40.29.
What is the P/E ratio for ELVN?
The P/E ratio (Price-to-Earnings) for ELVN is shown in the Key Statistics section. This valuation metric helps compare Enliven Therapeutics, Inc. to industry peers.
Does ELVN pay dividends?
Enliven Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for ELVN?
Based on ratings from 13 professional analysts over the last 90 days, the consensus for ELVN is Buy. The average 12-month price target is $74.45, a 89.3% upside from the Oct 15, 2026 close of $39.33.
What is the market cap of ELVN?
As of the Oct 15, 2026 close, Enliven Therapeutics's market capitalization is $2.60B, classifying it as a mid-cap company. Enliven Therapeutics operates in the Healthcare sector within the Biotechnology industry.